Shanghai Fosun Pharmaceutical (02196) subsidiary receives approval for clinical trials of 24-valent pneumococcal polysaccharide conjugate vaccine.

Shanghai Fosun Pharmaceutical (02196) announced that its holding subsidiary, Fosun AnTijin (Chengdu) Biopharmaceutical Co., Ltd. (hereinafter referred to as "Fosun AnTijin"), recently received approval from the National Medical Products Administration for the clinical trial of 24-valent pneumococcal polysaccharide conjugate vaccine (application registration classification: preventive biological product class 1.4; hereinafter referred to as "24-valent pneumococcal vaccine" or "the vaccine"). Fosun AnTijin plans to conduct Phase I clinical trials of the vaccine in China (excluding Hong Kong, Macau, and Taiwan) when conditions are met. The vaccine, independently developed by the group, is intended for prevention of infectious diseases caused by pneumococcal serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. The vaccine utilizes the group's platform technology with independently-owned intellectual property rights to combine polysaccharide antigens with carrier proteins, inducing T-cell-dependent immune responses and immune memory in individuals aged 6 weeks and above. As of January 2025, the group's total research and development investment for the vaccine is approximately RMB 44 million (unaudited). As of the date of this announcement (March 4, 2025), there are no approved 24-valent pneumococcal polysaccharide conjugate vaccines available for sale globally.